Quantum-Si Launches Platinum® Pro: The End-to-End Solution for Deeper Insights in Proteomics
Quantum-Si (Nasdaq: QSI) launches Platinum® Pro, a new benchtop sequencer aimed at revolutionizing protein analysis in proteomics research. The system is now available for ordering and features a comprehensive, integrated workflow designed to simplify complex protein sequencing.
Key innovations include an enlarged touchscreen with an elegant user interface, flexible data analysis options (local and cloud-based), and a Pro Mode for custom application development through a Technology Access Program. The product is intended to democratize access to proteomics, providing tools for diverse applications from proteoform analysis to protein barcoding.
CEO Jeff Hawkins emphasizes Platinum Pro's role in making proteomics more accessible, while Chief Commercial Officer Todd Bennett highlights a new partnership with Avantor, which will expand the product's availability in the U.S. and Canada. The system is expected to drive new opportunities for breakthrough discoveries and will begin shipping in the first quarter.
For more information or to place an order, visit Quantum-Si's website.
Quantum-Si (Nasdaq: QSI) lancia Platinum® Pro, un nuovo sequenziatore da banco progettato per rivoluzionare l'analisi delle proteine nella ricerca proteomica. Il sistema è già disponibile per gli ordini e presenta un flusso di lavoro integrato e completo, progettato per semplificare il sequenziamento complesso delle proteine.
Le principali innovazioni includono un touchscreen ampliato con un'interfaccia utente elegante, opzioni flessibili di analisi dei dati (locali e basate su cloud) e una modalità Pro per lo sviluppo di applicazioni personalizzate tramite un Programma di Accesso alla Tecnologia. Il prodotto mira a democratizzare l'accesso alla proteomica, fornendo strumenti per diverse applicazioni, dall'analisi dei proteoformi al codice a barre delle proteine.
Il CEO Jeff Hawkins sottolinea il ruolo di Platinum Pro nel rendere la proteomica più accessibile, mentre il Chief Commercial Officer Todd Bennett mette in evidenza una nuova partnership con Avantor, che espanderà la disponibilità del prodotto negli Stati Uniti e in Canada. Si prevede che il sistema genererà nuove opportunità per scoperte innovative e inizierà a spedire nel primo trimestre.
Per ulteriori informazioni o per effettuare un ordine, visita il sito web di Quantum-Si.
Quantum-Si (Nasdaq: QSI) lanza Platinum® Pro, un nuevo secuenciador de sobremesa dirigido a revolucionar el análisis de proteínas en la investigación proteómica. El sistema ya está disponible para pedidos y cuenta con un flujo de trabajo integral y completo diseñado para simplificar el secuenciamiento de proteínas complejas.
Las innovaciones clave incluyen una pantalla táctil ampliada con una interfaz de usuario elegante, opciones flexibles de análisis de datos (locales y basadas en la nube), y un Modo Pro para el desarrollo de aplicaciones personalizadas a través de un Programa de Acceso a Tecnologías. El producto está destinado a democratizar el acceso a la proteómica, proporcionando herramientas para diversas aplicaciones que van desde el análisis de proteoformas hasta la codificación de proteínas.
El CEO Jeff Hawkins enfatiza el papel de Platinum Pro en hacer la proteómica más accesible, mientras que el Director Comercial Todd Bennett destaca una nueva asociación con Avantor, que ampliará la disponibilidad del producto en los EE. UU. y Canadá. Se espera que el sistema genere nuevas oportunidades para descubrimientos innovadores y comenzará a enviarse en el primer trimestre.
Para más información o para realizar un pedido, visita el sitio web de Quantum-Si.
Quantum-Si (Nasdaq: QSI)가 Platinum® Pro를 출시했습니다. 이는 단백질 분석을 혁신할 수 있는 새로운 테이블탑 시퀀서로, 단백질체 연구에 초점을 맞추고 있습니다. 해당 시스템은 현재 주문 가능하며, 복잡한 단백질 서열 분석을 단순화하도록 설계된 포괄적이고 통합된 워크플로우를 제공합니다.
주요 혁신으로는 세련된 사용자 인터페이스를 갖춘 대형 터치스크린, 유연한 데이터 분석 옵션(로컬 및 클라우드 기반), 그리고 기술 접근 프로그램을 통한 맞춤형 애플리케이션 개발을 위한 Pro 모드가 포함되어 있습니다. 이 제품은 단백질체에 대한 접근성을 민주화하고, 단백질 변이 분석에서부터 단백질 바코딩에 이르기까지 다양한 응용 프로그램을 위한 도구를 제공합니다.
CEO인 Jeff Hawkins는 Platinum Pro가 단백질체 연구를 더 접근 가능하게 만드는 역할을 강조하며, 상업 담당 최고 책임자 Todd Bennett는 Avantor와의 새로운 파트너십이 미국과 캐나다에서 제품의 가용성을 확대할 것이라고 밝혔습니다. 이 시스템은 혁신적인 발견을 위한 새로운 기회를 창출할 것으로 기대되며, 첫 분기에 배송을 시작할 예정입니다.
자세한 정보나 주문을 원하시면 Quantum-Si의 웹사이트를 방문하세요.
Quantum-Si (Nasdaq: QSI) lance Platinum® Pro, un nouveau séquenceur de paillasse conçu pour révolutionner l'analyse des protéines dans la recherche en protéomique. Le système est désormais disponible à la commande et propose un flux de travail intégré et complet conçu pour simplifier le séquençage complexe des protéines.
Les principales innovations incluent un écran tactile agrandi avec une interface utilisateur élégante, des options d'analyse de données flexibles (locales et basées sur le cloud), et un mode Pro pour le développement d'applications sur mesure via un programme d'accès à la technologie. Le produit vise à démocratiser l'accès à la protéomique, fournissant des outils pour des applications variées allant de l'analyse de protéoformes à l'étiquetage des protéines.
Le PDG Jeff Hawkins souligne le rôle de Platinum Pro pour rendre la protéomique plus accessible, tandis que le directeur commercial Todd Bennett met en avant un nouveau partenariat avec Avantor, qui élargira la disponibilité du produit aux États-Unis et au Canada. Le système devrait créer de nouvelles opportunités pour des découvertes révolutionnaires et commencera à être expédié au premier trimestre.
Pour plus d'informations ou pour passer une commande, visitez le site web de Quantum-Si.
Quantum-Si (Nasdaq: QSI) bringt Platinum® Pro auf den Markt, einen neuen Tischsequenzierer, der darauf abzielt, die Proteinanalytik in der Proteomikforschung zu revolutionieren. Das System ist jetzt bestellbar und bietet einen umfassenden, integrierten Arbeitsablauf, der dazu dient, komplexe Proteinsequenzierung zu vereinfachen.
Wichtige Innovationen umfassen einen vergrößerten Touchscreen mit einer eleganten Benutzeroberfläche, flexible Datenanalyseoptionen (lokal und cloudbasiert) sowie einen Pro-Modus zur Entwicklung benutzerdefinierter Anwendungen über ein Technologiezugang-Programm. Das Produkt ist darauf ausgelegt, den Zugang zur Proteomik zu demokratisieren und bietet Werkzeuge für verschiedene Anwendungen, von der Proteoformanalyse bis hin zur Protein-Kodierung.
CEO Jeff Hawkins betont die Rolle von Platinum Pro dabei, die Proteomik zugänglicher zu machen, während der Chief Commercial Officer Todd Bennett eine neue Partnerschaft mit Avantor hervorhebt, die die Verfügbarkeit des Produkts in den USA und Kanada erweitern wird. Das System wird voraussichtlich neue Möglichkeiten für bahnbrechende Entdeckungen schaffen und beginnt im ersten Quartal mit dem Versand.
Weitere Informationen oder um eine Bestellung aufzugeben, besuchen Sie die Website von Quantum-Si.
- Launch of Platinum Pro, a next-generation benchtop sequencer, enhancing protein analysis capabilities.
- Partnership with Avantor extends product availability in the U.S. and Canada.
- Pro Mode feature supports custom application development, fostering biopharmaceutical innovation.
- Flexible data analysis options, including local and cloud-based solutions.
- None.
Insights
Quantum-Si's launch of Platinum® Pro marks a pivotal advancement in the proteomics instrumentation market. The platform's enhanced capabilities, including the new Pro Mode for custom application development, strategically positions QSI to capture market share in the rapidly growing $25 billion proteomics market. The partnership with Avantor significantly expands distribution capabilities, potentially accelerating market penetration in Q1 2024.
The system's dual-approach to data analysis - offering both local and cloud-based solutions - addresses a critical market need for flexible research infrastructure, particularly appealing to both academic and pharmaceutical customers. This flexibility could translate into broader market adoption and recurring revenue streams through potential cloud service subscriptions.
In simpler terms: Think of this as upgrading from a basic smartphone to a pro version - it's not just about better specs, but opening up new possibilities for how it can be used. The distribution deal with Avantor is like getting your product into major retail chains instead of selling it yourself - it's a game-changer for reaching customers.
The timing of this product launch aligns perfectly with the increasing demand for proteomics solutions in drug development and biomarker discovery. The introduction of Pro Mode through a Technology Access Program creates a strategic opportunity for partnership revenue streams with biopharmaceutical companies, potentially leading to significant deal flow in 2024.
The enhanced user interface and streamlined workflow directly address key adoption barriers in the proteomics market, potentially accelerating market penetration rates. This could translate into faster revenue growth compared to the original Platinum system, particularly given the expanded distribution network through Avantor.
Breaking it down simply: Quantum-Si has made their protein analysis machine easier to use and more powerful, while also getting a major distributor to help sell it. It's like having a better product and a bigger sales team at the same time - a powerful combination for growth.
The new Platinum® Pro system from Quantum-Si is now available to order. (Photo: Business Wire)
Platinum Pro delivers a comprehensive solution for sequencing and analyzing proteins in a simple, integrated workflow. Its design prioritizes accessibility, transforming complex protein sequencing into a seamless process for every lab, everywhere.
Platinum Pro is Quantum-Si’s newest Next-Generation Protein Sequencer™ built from the foundation of innovation established by the original Platinum. It introduces advanced features specifically tailored to address the evolving needs of researchers and biopharmaceutical customers. Its key innovations include:
- Streamlined User Experience: Platinum Pro features an enlarged touchscreen with an elegant user interface that guides the user through the course of a run enabling diverse applications from proteoform analysis to protein barcoding and beyond.
- Flexible Data Analysis: Users can perform data analysis locally or leverage cloud-based solutions, providing versatility to suit diverse research environments.
- Pro Mode: This feature empowers custom application development, offered through a Technology Access Program, making Platinum Pro a platform for biopharmaceutical innovation and co-development relationships.
“Platinum Pro represents a significant step forward in our mission to democratize access to proteomics,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “By combining ease of use with customizable features, we’re equipping researchers with the tools they need to unlock new frontiers in protein analysis.”
“The launch of Platinum Pro marks a major milestone for Quantum-Si as we continue to push the boundaries of proteomics,” said Todd Bennett, Chief Commercial Officer of Quantum-Si. “We are also thrilled to announce that our new partnership with Avantor is now in effect, which extends our reach, making Platinum Pro now available for ordering in the
Platinum Pro is the latest demonstration of Quantum-Si’s commitment to delivering cutting-edge solutions for next-generation protein sequencing. With its robust capabilities, the system is expected to drive new opportunities for breakthrough discoveries. Now available to order, Platinum Pro will begin shipping in the first quarter. To place an order or learn more about Platinum Pro, visit: The Protein Sequencing Company™ | Quantum-Si.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway and its financial guidance for the full year 2024. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113845303/en/
Investor
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
What is QSI's Platinum Pro?
How does the Platinum Pro benefit researchers?
When will Platinum Pro be available?
What are the key features of Quantum-Si's Platinum Pro?
What does the partnership with Avantor mean for QSI?
What is the Pro Mode in Platinum Pro?
How does Platinum Pro simplify protein sequencing?
Where can I order Quantum-Si's Platinum Pro?
